Innovating Clinical Trials
Welcome to Innovating Clinical Trials, the podcast designed for clinical research professionals eager to deepen their understanding of clinical trials through concise, insightful segments. Join your hosts, Liam Eves and Ted Trafford, as they uncover the core issues in clinical research, reflect on the industry, and challenge conventional wisdom.
Ted Trafford - https://probitymedical.com/
With 30 years of experience in clinical research, Ted serves as the Director of Business Development, driving business growth and leading Feasibility and Site Relationship teams at Probity Medical Research, a clinical trial site administrative support company with a consortium of 75+ sites across four countries. As a writer and speaker, Ted contributes to thought leadership and strategic initiatives in the clinical trials industry, leveraging his extensive experience and creative approach to drive meaningful discussion and progress for Sponsors, CROs, Sites and Technology Vendors.
Liam Eves - https://www.theendpointpodcast.com/
Liam's held executive roles in SMOs and CROs, and led all major functions of trial delivery. His journey into the field began unexpectedly after an injury ended his career as a professional footballer. Over the years Liam has optimized trial delivery methods / systems for effective enrollment and trial delivery. Currently, he focuses on building and advising companies in the clinical trial space.
Opinions expressed are those of the participants and not their employers.
Innovating Clinical Trials
ICT Ep 2.3: The Cost of Sponsors’ Extra Requests and what Sites can do about it
Welcome to Innovating Clinical Trials, the podcast designed for clinical research professionals eager to deepen their understanding of clinical trials through concise, insightful segments.
Join your hosts, Liam Eves and Ted Trafford, as they uncover the core issues in clinical research, reflect on the industry, and challenge conventional wisdom.
In this episode, Liam and Ted reveal how minor, unexpected requests often snowball into a significant site burden. They dive into why scope creep occurs, how sites can respond, and what sponsors can do to prevent it before it disrupts a study.